Today the company reported higher-than-expected results in the third quarter on surprisingly strong demand for its COVID-19 treatment, primarily in Japan, and raised its annual sales forecast for the therapy.
Tag Archive for: molnupiravir
The U.S. government will stop distributing free doses of Merck & Co.’s COVID-19 antiviral treatment molnupiravir by the middle of next month and expects it to be sold on the commercial market instead.
Merck had requested the regulator’s Committee for Medicinal Products for Human Use (CHMP) to re-examine the application for molnupiravir, which is sold under the brand Lagevrio in several countries, after CHMP advised against its market authorization in February.
Drugmaker Merck & Co. Inc. on Thursday posted better-than-expected results for the first quarter on the strength of its blockbuster cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil.
Pfizer and Merck have slightly lowered the prices of their respective Paxlovid and molnupiravir COVID-19 treatments in China, local media reported on Tuesday citing pricing information published by the province of Jiangsu.
Merck & Co. Inc. said on Tuesday its COVID-19 pill was not effective at cutting the risk of coronavirus infections in people living with someone infected with the virus.
Merck & Co. on Thursday forecast 2023 earnings below Wall Street estimates along with an expected steep decline in sales of its COVID-19 antiviral treatment, and its shares fell around 2%.
Sinopharm, now the China distributor of Merck & Co’s COVID-19 antiviral treatment molnupiravir, said its biotech unit received clinical trial approval from the National Medical Products Administration.
The company said today it would take legal action against some pharmaceutical companies after noticing that some manufacturers were supplying COVID-19 drugs to some provinces and cities saying the medicines were authorized by Merck.
Merck & Co. Inc.’s COVID antiviral molnupiravir speeds up recovery but does not reduce the hospitalization or death rate in higher-risk vaccinated adults, detailed data from a large study showed on Thursday.